BIRC5 and acute myeloid leukemia: The problem is that CTAs are often expressed in less patients (23% for HAGE [34] and 33% for PASD1 [35]) at AML presentation as compared with leukaemia associated antigens (LAAs), such as Survivin [42] and WT1 [43], which are found in most patients and can act as MRD markers in their own right.